|

177Lu-DOTATOC Clinical Trials

2 actively recruiting trials

No change since May 2026

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Lund University Hospital1
  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS1

Indications

  • Neuroendocrine Tumors2
  • Cancer2
  • Paraganglioma1
  • Pheochromocytoma1

Other2 trials

"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Phase 2
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.